LiDCO Group Plc
14 February 2006


For Immediate Release                                           14 February 2006



                                LIDCO GROUP PLC
                           ("LiDCO" or the "Company")

                                 Trading Update

LiDCO Group plc (AIM: LID), the cardiovascular monitoring company, is pleased to
announce that the expected net trading loss for the year to 31 January 2006 has
continued to reduce and is in line with market expectations.  The Company's
management remains committed to achieving profitability in the second half of
the current financial year.

Certain key capital sales orders have taken longer to achieve than previously
predicted and are now expected to occur in the current financial year.  As a
consequence, total revenue for the year to 31 January 2006 is expected to be up
to 15% below market expectations of £4 million.  However, the Company has
achieved significant margin improvements, with the result that the delayed sales
have not materially affected the Company's trading losses which continue to be
reduced as planned.  Following the recently announced further drawdown on the
Laurus convertible loan facility, the closing cash position at 31 January 2006
was approximately £1 million.

The installed base of monitors has grown during the year from 770 to over 920
and total sales in the year just ended are expected to be approximately 50%
higher than the equivalent previous 12 months (noting that the previous reported
period was 13 months).

The demand for cardiovascular monitoring equipment is growing steadily on a
world-wide basis and, within this overall growth in demand, the
minimally-invasive market, in which LiDCO is a leading player, is expanding
rapidly.  Encouragingly, the Company maintains a faster percentage growth rate
than its competitors and has made particularly good progress in its major
markets of the UK, Europe and USA, where there is the strongest competition.

Looking ahead, LiDCO has a strong sales pipeline and is pleased to note a trend
in prospective orders towards contracts of a relatively larger magnitude, such
as the US$456,000 order announced from the United States Army in November 2005.

Commenting on this announcement, Terry O'Brien, Chief Executive of LiDCO, said:

"I am pleased to report that LiDCO has made considerable progress in 2005.  With
high quality technology and an expanding customer base, we remain confident that
we shall continue to grow at a similar rate.  Management remains highly focused
on becoming profitable in the second half of this financial year and looks
forward to providing our investors with further information in due course."

LiDCO will announce its preliminary full year results on 26 April 2006.


                                   ---Ends---


For further information please contact:


LiDCO Group Plc                                         Tel: +44 (0)20 7749 1500
Terry O'Brien (CEO)
Hugh McGarel-Groves (FD)

Financial PR: Buchanan Communications                   Tel: +44 (0)20 7466 5000

Tim Anderson, Mary-Jane Johnson, James Strong

Broker: Panmure Gordon                                  Tel: +44 (0)20 7459 3600
Grant Harrison, Aubrey Powell, Katherine Roe



Notes for editors

About LiDCO Group Plc

LiDCO is a UK-based AIM-traded developer, manufacturer and leading supplier of
minimally invasive, computer-based hemodynamic monitoring equipment and
disposables used primarily for the management of critical care and
cardiovascular risk hospital patients. Use of LiDCO's technology has been shown
to significantly reduce the complications (particularly infections) and costs
associated with major surgery.  The technology was invented in the Department of
Applied Physiology based at St Thomas' Hospital, London where the Company
maintains a research base.

The Company's manufacturing facility is in London, UK and its current products
are:

LiDCOplus and PulseCO monitors: computer-based platforms for displaying a range
of real-time, continuous hemodynamic parameters including cardiac output, oxygen
delivery and fluid volume;

LiDCO disposables: used in conjunction with the LiDCOplus Monitor to accurately
determine cardiac output in a minimally-invasive manner.

Distribution Network:

The Company has now achieved registration of its products in 13 markets in
Europe, the USA, Brazil and Japan.  It sells direct to the NHS in the UK, and
through a worldwide network of specialty critical care distributors.




                      This information is provided by RNS
            The company news service from the London Stock Exchange